The effect of varying degrees of hepatic impairment on the single dose pharmacokinetic profile of orally administered lurasidone: a phase I study

Submission date	Recruitment status	Prospectively registered
29/01/2009	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
20/04/2009	Completed	Results
Last Edited	Condition category	[] Individual participant data
30/08/2011	Digestive System	[] Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Shelda Alcock

Contact details

Dainippon Sumitomo Pharma Europe Ltd 1st Floor, Southside 97 - 105 Victoria Street London United Kingdom SW1E 6QT

Additional identifiers

Protocol serial number D1050264

Study information

Scientific Title

The effect of varying degrees of hepatic impairment on the single dose safety and pharmacokinetic profile of lurasidone: an open-label phase I single dose non-randomised oral administration study

Study objectives

Primary: to assess the effect of varying degrees of hepatic impairment on the pharmacokinetics of lurasidone

Secondary: to assess the effect of varying degrees of hepatic impairment on the safety of

lurasidone

Ethics approval required

Old ethics approval format

Ethics approval(s)

- 1. Czech Republic: Ethics Committee for Clinical and Experimental Medicine and Faculty Thomayer Hospital approved 6th November 2008
- 2. Slovak Republic: Ethics Committee FNsP Bratislava approved 28th October 2008

Study design

Open-label phase I single dose non-randomised oral administration study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hepatic impairment

Interventions

All patients will receive a single oral 20 mg dose of lurasidone and be followed up for 9 days.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Lurasidone

Primary outcome(s)

Pharmacokinetics will be assessed as follows:

- 1. Primary parameters: AUC0-last, Cmax, calculated once at the completion of the trial, using data from blood samples collected from dosing up to 168 hours post-dose
- 2. Secondary parameters: AUC0-8, CL/F, tmax, $t\frac{1}{2}$, Vz/F and λ z, collected once at the completion of the trial, using data from blood samples collected from dosing up to 168 hours post-dose

Key secondary outcome(s))

Safety will be assessed by using the following endpoints:

- 1. Spontaneous adverse event reporting
- 2. Clinical laboratory tests (clinical chemistry including prolactin, haematology including coagulation, and urinalysis)
- 3. Concomitant medication review
- 4. Vital sign assessments (supine blood pressure, heart rate, and body temperature)
- 5. 12-lead ECG
- 6. Complete physical examinations

Collected once at the completion of the trial, using data from blood samples collected from dosing up to 168 hours post-dose.

Completion date

31/03/2009

Eligibility

Key inclusion criteria

Main criteria:

- 1. Subject is male or female
- 2. Subject is between 18 to 75 years of age, inclusive
- 3. Body mass index (BMI) between 18 to 34 kg/m^2, inclusive, and a minimum body weight of 50 kg
- 4. Subject is informed of the nature of the study and has given written consent prior to initiating any study procedure
- 5. Subjects able to comply with all aspects of the protocol

Hepatic impairment subjects:

- 6. Subjects with Child-Pugh Clinical Assessment Score consistent with degree of hepatic impairment
- 7. Subject's hepatic disease is deemed stable by the Investigator
- 8. Subject's pre-study clinical laboratory findings are within normal range or if outside of the normal range, deemed associated with underlying hepatic dysfunction or not clinically significant in the opinion of the Investigator

Normal hepatic function subjects:

9. Subject is considered to be in good health in the opinion of the Investigator, as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Subject has had a clinically significant intercurrent illness in the four weeks before screening
- 2. Subject shows evidence of a clinically significant underlying medical condition, that, in the opinion of the Investigator, would represent a risk of study participation
- 3. History of or suspicion of significant gastrointestinal bleeding within the preceding 2 months
- 4. Any disorder (other than hepatic impairment, appendectomy, and cholecystectomy) that may alter the absorption, distribution, metabolism or excretion of drugs
- 5. History of clinically significant drug allergy including a history of atopic allergy (asthma, urticaria, or eczematous dermatitis)
- 6. Pregnant or lactating female subjects

Date of first enrolment

12/11/2008

Date of final enrolment

31/03/2009

Locations

Countries of recruitment

United Kingdom

England

Czech Republic

Slovakia

Study participating centre
Dainippon Sumitomo Pharma Europe Ltd
London
United Kingdom
SW1E 6QT

Sponsor information

Organisation

Dainippon Sumitomo Pharma Europe Ltd (UK)

ROR

https://ror.org/03sh4z743

Funder(s)

Funder type

Industry

Funder Name

Dainippon Sumitomo Pharma Co., Ltd (Japan)

Alternative Name(s)

Dainippon Sumitomo Pharma Co., Ltd.

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Japan

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes